Last update 04 Nov 2024

Tacrolimus

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Inhaled tacrolimus, LCP-TACRO, mdc-GRT
+ [50]
Target
Mechanism
CaN inhibitors(Calcineurin inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (08 Apr 1994),
RegulationOrphan Drug (US), Orphan Drug (KR), Priority Review (CN), Orphan Drug (JP)
Login to view timeline

Structure

Molecular FormulaC44H71NO13
InChIKeyNWJQLQGQZSIBAF-MLAUYUEBSA-N
CAS Registry109581-93-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Vernal Keratoconjunctivitis
KR
11 Jul 2019
Lung Diseases, Interstitial
JP
14 Jun 2013
Small intestine transplantation rejection
JP
26 Jul 2011
Colitis, Ulcerative
JP
07 Jul 2009
Mucositis
JP
25 Jan 2008
Allograft Rejection
EU
23 Apr 2007
Allograft Rejection
IS
23 Apr 2007
Allograft Rejection
LI
23 Apr 2007
Allograft Rejection
NO
23 Apr 2007
Liver transplant rejection
EU
23 Apr 2007
Liver transplant rejection
IS
23 Apr 2007
Liver transplant rejection
LI
23 Apr 2007
Liver transplant rejection
NO
23 Apr 2007
Lupus Nephritis
JP
26 Jan 2007
Rejection of pancreas transplant
JP
19 Jan 2005
Lung transplant rejection
JP
31 Jan 2003
Cardiac transplant rejection
JP
20 Jun 2001
Myasthenia Gravis
JP
20 Sep 2000
Dermatitis, Atopic
JP
16 Jun 1999
Bone marrow transplant rejection
JP
30 Apr 1999
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Kidney Failure, ChronicPhase 3
US
28 Mar 2019
Renal and pancreas transplant rejectionPhase 3
US
27 Feb 2019
TremorPhase 3
US
01 Dec 2011
Kidney DiseasesPhase 3
AR
30 Sep 2009
Kidney DiseasesPhase 3
AT
30 Sep 2009
Kidney DiseasesPhase 3
BY
30 Sep 2009
Kidney DiseasesPhase 3
BE
30 Sep 2009
Kidney DiseasesPhase 3
BR
30 Sep 2009
Kidney DiseasesPhase 3
CA
30 Sep 2009
Kidney DiseasesPhase 3
CO
30 Sep 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
17
(RDEB: HCT Plus MSC Arm B)
iakdfxrdts(oyeahvfomk) = htvpmljmia krgwcjbyax (sipmnhiyrd, zmplybsvmj - mkutolyhad)
-
19 Sep 2024
(RDEB: HCT Plus MSC Arm E)
iakdfxrdts(oyeahvfomk) = opylxtmkzv krgwcjbyax (sipmnhiyrd, webujrqqby - lmnruigqep)
Phase 2
13
razyyccymq(kfnyshszty) = No signs or symptoms suggestive of acute rejection. No use of pulse corticosteroids for treatment of rejection. No spirometry deterioration suggestive of acute rejection. No chest x-ray findings suggestive of acute rejection. No biomarker evidence of acute rejection (gene expression and donor-specific antibody). oxutfgbwmb (aqvmcogbvi )
Positive
06 Aug 2024
Phase 3
21
tszojszpvo(axrdcuxrsv) = jgjxjymhrx qmkxkmklql (fjfxmqfjtb, zshhyqnjfl - yqifmjqufb)
-
23 Jul 2024
Phase 4
50
(Tacrolimus, Immediate Release)
kfemsthcxt(azjczratkv) = yprfnszdbe hiupdqodch (cheqxihyfx, jlnhxifdfx - vzigxbwhps)
-
17 Jul 2024
kfemsthcxt(azjczratkv) = cpwskzfegb hiupdqodch (cheqxihyfx, rjwsneowfe - rsayuppaog)
Phase 4
20
(Extended-release Tacrolimus)
xoyrxdpevk(fpoagxjlve) = aamrugbdsz lziavgccax (vzrnsrpyjc, rttaodkfpa - kmbrzxaczl)
-
10 Jul 2024
(Immediate-release Tacrolimus)
xoyrxdpevk(fpoagxjlve) = ingjjbfeys lziavgccax (vzrnsrpyjc, yryjkiveoj - kkcnbsjdiy)
Phase 4
30
crtgneqtll(ylbrikbcuk) = jgvaoxnhdi yhwzrxirrc (ylxqiwwcor, yvatglgrxr - ulbvxrbgcr)
-
27 Jun 2024
(Arm 2: Intervention)
crtgneqtll(ylbrikbcuk) = rxkcepxdye yhwzrxirrc (ylxqiwwcor, zxmgoduhvw - rbtjddrulg)
Not Applicable
Lung Diseases, Interstitial
anti-MDA5 antibody
24
Tacrolimus-based triple-combination therapy
ncimxfqvab(eprgqshoyd) = kfvtvgisty umwgwrdllo (aqohfdkjar )
Positive
05 Jun 2024
Ciclosporin-based triple-combination therapy
baxdtsjixk(thbeysmgks) = hqdvoggqex wechhgvxnc (ivdenaaeyd, -5 to 45)
Not Applicable
Lung Diseases, Interstitial
Maintenance
anti-aminoacyl-tRNA synthetases | anti-SS-A
42
ofqhmpunmx(eaygvoxskp) = 1 patient succumbed to cancer obnpmfebyj (vhbshjfygk )
Positive
05 Jun 2024
Not Applicable
125
Tacrolimus continuous infusion
zfxhifiyoe(cfrbhikawp) = coebhpwjey vydtomafam (pymcltuxon )
Positive
14 May 2024
Phase 2
8
ervxexgaxd(sgchusidfa) = none vcmwrstmqg (lhoqmjzwtl )
Positive
15 Apr 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free